

Cancer
Specialised Cancer Surgery
Cancer: Malignant Mesothelioma (Adult)

B10/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
CMM01	Proportion of new mesothelioma patients who receive an MDT discussion	Of those in the denominator, the number of patients receiving an MDT discussion	The total number of new mesothelioma patients during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM02	Proportion of patients with a confirmed diagnosis recorded as having seen a Mesothelioma or a Lung Cancer Nurse Specialist	Of those in the denominator, the patients recorded as having seen a Mesothelioma or Lung CNS following diagnosis	The total number of new mesothelioma patients with a confirmed diagnosis during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM03	Proportion of those patients with pathological confirmation where histological subtype is identified	Of those in the denominator, the number of patients with pathological confirmation where histological subtype is identified	The total number of new patients where diagnosis is confirmed pathologically in the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM04	Proportion of patients whose tumour stage is recorded at diagnosis	Of those in the denominator, the number of patients with mesothelioma who have a tumour stage recorded at diagnosis	The total number of new mesothelioma patients with a confirmed diagnosis during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM05	Proportion of patients whose performance status is recorded at diagnosis	Of those in the denominator, the number of patients with mesothelioma who have a performance status recorded at diagnosis	The total number of new mesothelioma patients with a confirmed diagnosis during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM06	Proportion of patients of PS 0-1 receiving chemotherapy	Of those in the denominator, the number of patients who receive chemotherapy	The total number of patients with a PS 0-1	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM07	Proportion of patients receiving radical surgery (EPP or radical decortication)	Of those in the denominator, the number of patients who receive radical surgery	The total number of new mesothelioma patients during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM08	Proportion of patients being entered into a clinical trial /research study	Of those in the denominator, the number of new patients entering a clinical trial	The total number of new mesothelioma patients during the reporting period	Quarter	Quarterly	Provider	Provider			Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
CMM09	Proportion of patients alive at 1 year from diagnosis	Of those in the denominator, the number of patients alive at 1 year post diagnosis	The total number of new mesothelioma patients with a confirmed diagnosis during the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-21 - Mar-22
CMM10	Proportion of patients alive at 2 years from diagnosis	Of those in the denominator, the number of patients alive at 2 years post diagnosis	The total number of new mesothelioma patients with a confirmed diagnosis during the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-20 - Mar-21